Sharing Knowledge in Smallcaps

[streetshooter]

CLN @ 1.14( Giving this one a serious look.)

Came across this biotech on a Bollinger Band consolidation scan with
a 3x10 MA cross over and a MACD cross over all within very tight
bands.
Conference call tomorrow,dont see any big sales, but should get a
update on current status of their tech.

Trouble is i will be at work with PC access, so i will have to take
a chance on buying before CC at the open with a order tonite.

As tight as the bands are, any good news could send this in a break
out mode.


http://stockcharts.com/def/servlet/SC.web?c=cln,uu[m,a]daclyyay[dd]
[pb10!b40!d20,2][vc60][iLh33,11!Lv25!La12,26,9!Lc20!Lf!Lm12!Lb14]
&pref=G


Celsion Corporation develops medical treatment systems primarily to
treat breast cancer and a chronic prostate enlargement condition,
common in older males, known as benign prostatic hyperplasia (BPH),
using minimally invasive focused heat technology. The Company is also
working with Duke University on the development of heat-sensitive
liposome compounds for use in the delivery of chemotherapy drugs to
tumor sites and with the Memorial Sloan-Kettering Cancer Center
(Sloan-Kettering) on the development of heat-activated gene therapy
compounds.


Stock Price History
Beta: 2.705
52-Week Change: 186.49%
52-Week Change (relative to S&P500): 150.26%
52-Week High (19-Jun-03): 1.80
52-Week Low (10-Oct-02): 0.36
50-Day Moving Average: 1.05
200-Day Moving Average: 0.67


Share Statistics
Average Volume (3 month): 1,362,227
Average Volume (10 day): 509,000
Shares Outstanding: 112.72M
Float: 127.50M
% Held by Insiders: N/A
% Held by Institutions: N/A
Shares Short (as of 8-Aug-03): 1.40M
Daily Volume (as of 8-Aug-03): N/A
Short Ratio (as of 8-Aug-03): 1.295
Short % of Float (as of 8-Aug-03): 1.10%
Shares Short (prior month): 1.11M


Dividends & Splits
Annual Dividend: N/A
Dividend Yield: 0.00%
Dividend Date: N/A
Ex-Dividend Date: N/A
Last Split Factor (new per old)²: N/A
Last Split Date: N/A



Total Cash (mrq): 5.50M
Total Cash Per Share (mrq): 0.04
Total Debt (mrq)²: 0
Total Debt/Equity (mrq): 0
Current Ratio (mrq): 5.981
Book Value Per Share (mrq): 0.01

Significant Events:

Webcast Alert: Celsion Corporation Announces Presentation at Redchip Partners Fall New York Investor Conference 2003 Webcast
Monday September 15, 5:25 pm ET


COLUMBIA, Md., Sept. 15 /PRNewswire-FirstCall/ -- Celsion Corporation (Amex: CLN - News) announces the following Webcast:
What: CLN Presentation at Redchip Partners Fall New York
Investor Conference 2003 Webcast

When: Sept. 18, 2003 @ 10:30 a.m. Eastern

Where: http://www.firstcallevents.com/service/ajwz388632037gf12.html

How: Live over the Internet -- Simply log on to the web at the





Celsion Acquires Duke University's Breast Cancer Hyperthermia Treatment Technology
Thursday August 7, 9:48 am ET


COLUMBIA, Md.--(BUSINESS WIRE)--Aug. 7, 2003--
Celsion has obtained exclusive rights to an advanced phased array radio frequency (RF) heating system designed specifically for use with chemotherapeutic drugs for the treatment of locally advanced breast cancer.

American Medical Association Assigns CPT Code to Celsion's Breast Cancer Treatment System
Thursday July 24, 9:48 am ET


COLUMBIA, Md.--(BUSINESS WIRE)--July 24, 2003--Celsion Corporation (AMEX:CLN - News) today announced that the CPT (Current Procedural Terminology) Editorial Panel of the American Medical Association (AMA) has assigned a new CPT code for thermal therapy for ablation/reduction of malignant breast tumors. This new CPT code applies to breast cancer treatment procedures using Celsion's proprietary investigational Adaptive Phased Array (APA) thermal therapy system. The assignment of the new CPT code by the AMA recognizes Celsion's proprietary breast cancer therapy as an emerging technology for the management of breast cancer.



Celsion Announces $9.6 Million in New Capital
Tuesday July 8, 9:11 am ET


COLUMBIA, Md.--(BUSINESS WIRE)--July 8, 2003--Celsion Corporation (AMEX:CLN - News), announced today that it has raised a total of $5.1 million through the exercise of outstanding common stock purchase warrants since May 28, 2003 and expects to realize gross proceeds of $4.5 million in a private placement of its common stock and associated warrants in a private placement expected to close today.



'Cancer Research' Publishes Promising Pre-Clinical Results on Celsion's Heat-Activated Gene Therapy Technology
Thursday June 19, 10:28 am ET


COLUMBIA, Md.--(BUSINESS WIRE)--June 19, 2003--Celsion Corporation (AMEX:CLN - News) today announced the publication, in "Cancer Research", Volume 63, dated June 15, 2003, of the results of pre-clinical research by Dr. Gloria Li, Attending Biophysicist at Memorial Sloan-Kettering Cancer Center in New York City. The article provides a comprehensive summary of the scientific and clinical rationale leading to the successful development of a heat-activated antisense genetic biological modifier and the preclinical evaluations, which demonstrated the feasibility of its use as a potent radiation sensitizer for the treatment of cancer.